+ 0.89
+ 0.26%
+ 0.07
+ 0.02%
+ 0.75
+ 0.18%

Why Novavax Is Moving Today

May 12, 2021 9:11 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower by 3.7% at $133.05 after JPMorgan downgraded the stock from Overweight to Neutral and lowered its price target from $285 to $161 per share.

Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly-owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

Novavax Shares Jump After UK Vaccine Trial: Technical Levels To Watch

Novavax Inc. (NASDAQ: NVAX) shares were rallying Friday following the announcement of data from the company's U.K. coronavirus vaccine trial. read more

Benzinga's Bulls And Bears Of The Week: Apple, Salesforce, Tesla And More

Benzinga has examined the prospects for many investor favorite stocks over the past week. This past week's bullish calls included the iPhone maker and other tech leaders. The leading EV maker and a top biotech were among the bearish calls. read more

PreMarket Prep Stock Of The Day: Moderna

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. read more

Heating Up: Three Leveraged ETFs For Summer Earnings

As the broad market knocks on the door of all-time highs in the midst of a still-raging public health crisis, traders have had to simultaneously ride the bullish wave (in most sectors) while also moderating their expectations for corporate earnings. read more